<DOC>
	<DOCNO>NCT02102451</DOCNO>
	<brief_summary>The purpose study evaluate feasibility rapid scale-up new hepatitis C ( HCV ) treatment , know interferon-free Direct Acting Antiviral ( DAA ) drug , impact proportion people HCV within HIV-HCV coinfected population Australia . It hypothesise rapid scale-up hepatitis C treatment interferon-free therapy individual HIV-HCV coinfection assist control HCV infection population .</brief_summary>
	<brief_title>Control Elimination Within Australia Hepatitis C From People Living With HIV</brief_title>
	<detailed_description>This project five major component occur independently link central theme control eliminate HCV infection majority Australian HIV positive population . Database HIV-HCV individual ( CEASE-D ) : Surveillance HIV-HCV positive individual occur enrolment CEASE-D observational study database . The proportion HCV viraemia population determine three cross-sectional survey ; enrolment ( 2014-2015 ) , follow-up 1 ( 2016 ) follow-up 2 ( 2018 ) . Participation involve provide inform consent , collection limit clinic demographic information , dry blood spot sample , patient complete CEASE questionnaire FibroScan® ( available ) . It estimate approximately 1000 HIV-HCV coinfected individual enrol CEASE-D database . Modelling ( CEASE-M ) : Mathematical model undertaken examine various treatment strategy , include HCV treatment scale-up timeline . The data first cross-sectional survey HCV surveillance phase ( CEASE-D ) inform component model . HCV Education HIV prescribers ( CEASE-E ) : A comprehensive education program HCV treatment interferon-free DAA therapy conduct HIV prescribers high HCV caseloads preparation rapid scale-up HCV treatment . HCV Treatment Scale-Up ( CEASE-T ) : HCV treatment scale‐up PBS list regimen involve primary tertiary clinic . All patient commence HCV treatment invite participate CEASE‐T involve data collection regard treatment PBS list regimen . The regimen duration determine treat clinician accord PBS prescribing guideline . At select site subject offer enrollment intensive follow‐up substudy ( I‐STEP ) involve collection research EDTA plasma sample , patient complete behavioural questionnaire FibroScan® ( available ) . Patients recurrent viraemia follow treatment ( relapse/reinfection ) may also enter separate substudy cohort ( CEASE‐V ) Recurrent Viraemia Treatment ( CEASE-V ) At select site patient on‐treatment virological failure ( nonresponse viral breakthrough ) post‐treatment recurrent viraemia ( relapse reinfection ) enter intensive follow‐up cohort ( CEASE‐V ) . Participation involve provide inform consent , collection research EDTA plasma sample patient complete behavioural questionnaire . Patients may offer retreatment PBS list regimen . The decision retreat well regimen duration determine treat clinician accord PBS prescribing guideline</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<criteria>CEASED : 1 . 18 year age old 2 . Voluntarily sign informed consent form 3 . HIV positive 4 . HCV antibody positive 5 . Adequate English mental health status provide write informed consent comply study procedure CEASET ( ISTEP ) : 1 . 18 year age old 2 . Voluntarily sign informed consent form 3 . HIV positive 4 . HCV RNA positive 5 . Adequate English mental health status provide write informed consent comply study procedures 6 . Undergoing DAA therapy HCV treatment . CEASEV : 1 . 18 year age old 2 . Voluntarily sign informed consent form 3 . HIV positive 4 . Undergone IFN‐free DAA therapy HCV 6 ) On treatment virological failure post‐treatment recurrent viraemia define either : ) Non‐response : Failure viral suppression IFN‐free DAA therapy b ) Virological breakthrough IFN‐free DAA therapy c ) Post‐treatment recurrent viraemia : Detectable HCV RNA post‐treatment follow end‐of‐treatment response ( ETR , undetectable HCV RNA end treatment ) CEASED : 1 ) Inability willingness comply protocol requirement CEASET : 1 ) Inability willingness comply protocol requirement CEASEV : 1 ) Inability willingness comply protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Interferon-free</keyword>
	<keyword>Direct act antiviral ( DAA )</keyword>
	<keyword>Treatment prevention</keyword>
	<keyword>Surveillance</keyword>
	<keyword>Feasibility</keyword>
</DOC>